retatrutide trial FDA Approval Status 2026: Everything We Know So Far Trial of next-gen weight-loss drug

Ten milligrams of active compound, sitting as a white or off-white powder at the bottom of a small glass vial, waiting to be reconstituted into an injectable solution

Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%

Meanwhile, Point32Health, which owns Harvard Pilgrim and Tufts Health Plan, reported operating income of $86 million for the quarter, after losing $39 million in the same period of 2025

This can be valuable during the titration phase when managing side effects

That is why the protocol uses once-weekly dosing

Others may feel unsure about mild side effects and consider stopping treatment too soon